Published online Feb 28, 2006. doi: 10.3748/wjg.v12.i8.1312
Revised: October 15, 2005
Accepted: October 26, 2005
Published online: February 28, 2006
AIM: To evaluate the functions of a new bioartificial liver (BAL) system in vitro and in vitro.
MEHTODS: The BAL system was configurated by inoculating porcine hepatocyte spheroids into the cell circuit of a hollow fiber bioreactor. In the experiments of BAL in vitro, the levels of alanine aminotransferase (ALT), total bilirubin (TB), and albumin (ALB) in the circulating hepatocyte suspension and RPMI-1640 medium were determined during 6 h of circulation in the BAL device. In the experiments of BAL in vitro, acute liver failure (ALF) model in canine was induced by an end-side portocaval shunt combined with common bile duct ligation and transaction. Blood ALT, TB and ammonia levels of ALF in canines were determined before and after BAL treatment.
RESULTS: During 6 h of circulation in vitro, there was no significant change of ALT, whereas the TB and ALB levels gradually increased with time both in the hepatocyte suspension and in RPMI-1640 medium. In the BAL treatment group, blood ALT, TB and ammonia levels of ALF in canines decreased significantly.
CONCLUSION: The new BAL system has the ability to perform liver functions and can be used to treat ALF.